On November 7, 2025, Personalis, Inc. announced that its NeXT Personal® test received Medicare coverage for monitoring cancer recurrence in stage II and III breast cancer patients, retroactive to October 7, 2025; reimbursement rates are $3,878 for the breast cancer test and $1,158 for the plasma test.